Gut health drugs firm EnteroBiotix raises £19m – Daily Business
1 min read
James McIlroy: building in Scotland
Drugs developer EnteroBiotix has raised £19 million in one of the largest investments into a Scottish biotech company in recent years.
It will support one of the world’s most extensive clinical trials of treatments for irritable bowel syndrome (IBS).
IBS affects up to 1 in 10 of the global population, with up to twice as many women diagnosed compared to men.
The trial involving around 300 patients is now under way, with the drug manufactured by EnteroBiotix in Scotland. Results from the trial are due in the second half of 2027.
The funding round was led by life science investor Thairm Bio and the Scottish National Investment Bank, with participation from existing investors.
EnteroBiotix has raised in excess of £65m since the company was founded by CEO Dr James McIlroy in 2017. He launched the company while training to be a doctor.
“We aim to address underlying disease biology and deliver clinically meaningful improvements in patient outcomes,” he said.
“Our mission is to redefine the standard of care in gastrointestinal disease, improving the lives of patients with IBS while building a leading global biopharmaceutical company from our base in Scotland.”
EnteroBiotix’s clinical pipeline spans IBS, liver cirrhosis, and blood cancer. The company, which is chaired by former Merck Serono CEO Elmar Schnee, has a number of strategic partnerships and research collaborations in place, including with Imperial College London.
#Gut #health #drugs #firm #EnteroBiotix #raises #19m #Daily #Business